These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37185251)

  • 1. Kymriah® (tisagenlecleucel) - An overview of the clinical development journey of the first approved CAR-T therapy.
    Awasthi R; Maier HJ; Zhang J; Lim S
    Hum Vaccin Immunother; 2023 Dec; 19(1):2210046. PubMed ID: 37185251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case report: CD7-targeted autologous CAR-T therapy for the treatment of T-cell acute lymphoblastic leukemia undergoing allogeneic peripheral blood stem cell transplantation in the long-term follow-up.
    Li LL; Xia YP; Li Q; Wang P; Sun PP; Wang XG; Zhang R
    Front Immunol; 2024; 15():1469251. PubMed ID: 39620223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world Outcomes of Commercial Tisagenlecleucel for Children, Adolescents, and Young Adults With Acute Lymphoblastic Leukemia in Japan.
    Kato I; Tomizawa D; Kato M; Hirabayashi S; Manabe A; Irie M; Sasahara Y; Arakawa Y; Koh K; Sakaguchi H; Sugiyama M; Ogawa C; Kamiya T; Saito S; Nakazawa Y; Nishio N; Takahashi Y; Iwai N; Adachi S; Takita J; Miyamura T; Yokoyama S; Oba U; Ueda T; Koga Y; Hiramatsu H
    Transplant Cell Ther; 2024 Nov; ():. PubMed ID: 39617098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.
    Shah BD; Ghobadi A; Oluwole OO; Logan AC; Boissel N; Cassaday RD; Leguay T; Bishop MR; Topp MS; Tzachanis D; O'Dwyer KM; Arellano ML; Lin Y; Baer MR; Schiller GJ; Park JH; Subklewe M; Abedi M; Minnema MC; Wierda WG; DeAngelo DJ; Stiff P; Jeyakumar D; Feng C; Dong J; Shen T; Milletti F; Rossi JM; Vezan R; Masouleh BK; Houot R
    Lancet; 2021 Aug; 398(10299):491-502. PubMed ID: 34097852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic B-lineage leukemia in children and young adults.
    Feuchtinger T; Bader P; Subklewe M; Breidenbach M; Willier S; Metzler M; Gökbuget N; Hauer J; Müller F; Schlegel PG; Frühwald M; Schmid C; Troeger A; Baldus C; Meisel R; Künkele A; Topp M; Bourquin JP; Cario G; Von Stackelberg A; Peters C
    Haematologica; 2024 Dec; 109(12):3892-3903. PubMed ID: 38356450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes with chimeric antigen receptor T-cell therapy in Rheumatological disorders: A systematic review.
    Zulfiqar F; Shahzad M; Amin MK; Vyas A; Sarfraz Z; Zainab A; Qasim H; Kaur D; Khavandgar N; Lutfi F; Hematti P; McGuirk JP; Mushtaq MU
    Transpl Immunol; 2024 Dec; 87():102137. PubMed ID: 39442586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer: A Nonrandomized Clinical Trial.
    Chen N; Pu C; Zhao L; Li W; Wang C; Zhu R; Liang T; Niu C; Huang X; Tang H; Wang Y; Yang H; Jia B; Jiang X; Han G; Wang W; Chen D; Wang Y; Rowinsky EK; Kennedy E; Lu VX; Cui G; Wu Z; Xiao L; Cui J
    JAMA Oncol; 2024 Nov; 10(11):1532-1536. PubMed ID: 39298141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing cancer treatment: the synergistic potential of CAR-T cell therapy and CRISPR/Cas9.
    Amiri M; Moaveni AK; Majidi Zolbin M; Shademan B; Nourazarian A
    Front Immunol; 2024; 15():1462697. PubMed ID: 39582866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical efficacy and safety of blinatumomab bridging CAR-T cell therapy in the treatment of patients with adult acute B-cell lymphoblastic leukemia].
    Pu Y; Zhou XY; Liu Y; Kong X; Han JJ; Zhang J; Lin ZH; Chen J; Qiu HY; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):339-344. PubMed ID: 38951060
    [No Abstract]   [Full Text] [Related]  

  • 10. BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple Myeloma.
    Wang T; Yang Y; Ma L; Feng R; Li J; Zhang C; Bai J; Ding Y; Liu G; Wu F; Lu X; Feng S; Li Z; He T; Li J; Liu H
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39313307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant Advancements and Evolutions in Chimeric Antigen Receptor Design.
    Gaimari A; De Lucia A; Nicolini F; Mazzotti L; Maltoni R; Rughi G; Zurlo M; Marchesini M; Juan M; Parras D; Cerchione C; Martinelli G; Bravaccini S; Tettamanti S; Pasetto A; Pasini L; Magnoni C; Gazzola L; Borges de Souza P; Mazza M
    Int J Mol Sci; 2024 Nov; 25(22):. PubMed ID: 39596267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study.
    Iyer SP; Sica RA; Ho PJ; Prica A; Zain J; Foss FM; Hu B; Beitinjaneh A; Weng WK; Kim YH; Khodadoust MS; Huen AO; Williams LM; Ma A; Huang E; Ganpule A; Nagar SD; Sripakdeevong P; Cullingford EL; Karnik S; Dequeant ML; Patel JN; He XS; Li Z; He QA; Mendonez JH; Keegan A; Horwitz SM
    Lancet Oncol; 2024 Nov; ():. PubMed ID: 39617017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL.
    Linhares Y; Freytes CO; Cherry M; Bachier C; Maris M; Hoda D; Varela JC; Bellomo C; Cross S; Essell J; Fanning S; Terebelo H; Yimer H; Courtright J; Sharman JP; Kostic A; Vedal M; Ogasawara K; Avilion A; Espinola R; Yuan B; Mattar B
    Blood Adv; 2024 Dec; 8(23):6114-6126. PubMed ID: 39347584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infectious complications in pediatric patients undergoing CD19+CD22+ chimeric antigen receptor T-cell therapy for relapsed/refractory B-lymphoblastic leukemia.
    Wu X; Cao Z; Chen Z; Wang Y; He H; Xiao P; Hu S; Lu J; Li B
    Clin Exp Med; 2024 Apr; 24(1):87. PubMed ID: 38662121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Current State of Chimeric Antigen Receptor T Cell Therapy for B Lymphoblastic Leukemia.
    McClory SE; Maude SL
    Hematol Oncol Clin North Am; 2023 Dec; 37(6):1041-1052. PubMed ID: 37500380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of potent TCR-T cells specific for cisplatin-resistance related tumor-associated antigen, CLSPN using codon-optimization.
    Hori K; Yamada S; Murata K; Miyata H; Mizue Y; Murai A; Minowa T; Sasaki K; Shijubou N; Kubo T; Morita R; Tokita S; Kanaseki T; Tsukahara T; Abe T; Shinohara N; Hirohashi Y; Torigoe T
    Hum Vaccin Immunother; 2024 Dec; 20(1):2414542. PubMed ID: 39539024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Construction of CD138-targeted chimeric antigen receptor- modified T cells and their effect in multiple myeloma therapy].
    Guo CC; Lu Y; Tang KJ; Xing HY; Tian Z; Rao Q; Wang M; Xiong DS; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2024 May; 45(5):436-444. PubMed ID: 38964917
    [No Abstract]   [Full Text] [Related]  

  • 18. BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma.
    Yan Y; Tu Y; Cheng Q; Zhang J; Wang E; Deng Z; Yu Y; Wang L; Liu R; Chu L; Kang L; Liu J; Li X
    J Transl Med; 2024 Nov; 22(1):1087. PubMed ID: 39614361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applications and Opportunities for Immune Cell CAR Engineering in Comparative Oncology.
    Rotolo A; Atherton MJ
    Clin Cancer Res; 2024 Jun; 30(11):2359-2369. PubMed ID: 38573683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor T-cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice.
    Grégoire C; Coutinho de Oliveira B; Caimi PF; Caers J; Melenhorst JJ
    Br J Haematol; 2024 Nov; 205(5):1699-1713. PubMed ID: 39262037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.